LCA-NY issues 2009 Report Card on Lung Cancer

Today, Lung Cancer Alliance-New York (LCA-NY) issued its 1st Report Card on Lung Cancer. This Report is an assessment of progress being made against lung cancer in the state of New York. LCA-NY is a chapter of Lung Cancer Alliance (LCA), the only national organization dedicated exclusively to patient support and advocacy for people living with or at risk for lung cancer.

Lung cancer is the number one cause of cancer deaths both nationally and in New York. This year alone, 13,550 New Yorkers will be diagnosed and 8,780 will die from the disease -- more than breast, prostate, and colon cancers combined.

"Despite these alarming statistics, the New York legislature and Department of Health have not put together a comprehensive, coordinated plan to address lung cancer," said Phyllis Goldstein, LCA-NY Chair. "State funding for lung cancer prevention, early detection, better treatments and research must increase if we are going to see a reduction in mortality rates in New York."

"LCA-NY has laid out their commitments to reversing the decades of stigma and neglect associated with lung cancer," said Laurie Fenton Ambrose, LCA President and CEO. "They have a team in place willing to work with other organizations who share their common goals laid out in their 2009 Report Card on Lung Cancer."

The LCA-NY 2009 Report Card on Lung Cancer uses six categories to annually grade progress in key benchmarks areas in order to alert New York public health and public policy leaders and state residents to what needs to be done to address lung cancer appropriately.

Over the past four decades, significant funding for research and early detection has greatly increased five year survival rates for breast cancer (88 percent), prostate cancer (99 percent) and colon cancer (65 percent).

Under-funded and ignored, the lung cancer five year survival rate is still only 15 percent.

The LCA-NY 2009 Report Card on Lung Cancer grades the following six categories:

  • Number of Deaths -- GRADE: F Lung cancer is the number one cause of cancer death among New York men and women.
  • Five-Year Survival Rate -- GRADE: F Lung cancer is the only major cancer with virtually no improvement in survival for nearly 40 years, and a five year survival rate that has hovered at 15 percent.
  • Number of Late-Stage Diagnoses -- GRADE: F Lung cancer is under-funded and under-researched relative to its public health impact in New York.
  • Number of Newly-Addicted Youth Smokers -- GRADE: F Over 20,000 new "daily" smokers under age 18 become addicted each year in New York.
  • State-Supported Research -- GRADE: D Though there has been no legislation introduced in the state assembly or no lung cancer program in the Governor's budget, support for federal legislation, the Lung Cancer Mortality Reduction Act of 2009, is growing from New York federal legislators.
  • State Cancer Plan Commitment -- GRADE: D The 2003-2010 State Cancer Plan includes important support for tobacco cessation programs, but fails to include strategies to support early detection and treatment options.

"It is time to make a change," continued Goldstein. "LCA-NY will make sure that New York's outstanding hospitals and research centers play a major role in the effort to improve outcomes for the lung cancer."

For more information on the services provided by the Lung Cancer Alliance or to view the complete LCA-NY 2009 Report Card on Lung Cancer, visit the LCA-NY web page: www.lungcanceralliance.org/newyork

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances in bladder cancer treatments offer hope for curative care